ImmunoGen

Companies ImmunoGen

News ImmunoGen

• ImmunoGen, Inc. Announces Collaboration for Rights to Use ImmunoGen’s TAP Technology

  ImmunoGen, Inc.announced that it has entered into a collaboration agreement with Novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by Novartis. Under this agreement, Novartis will pay a $45 million upfront fee to ImmunoGen for more

• New Biotechnology Company: Immunovo BV

  Immunovo BV, a new biotechnology company developing a novel technology platform for the creation of a new generation of immunotherapeutics, has secured seed funding from Biox Biosciences BV and LUPUS Ventures BV. Immunovo combines features of synthetic immunogen development with the recent insights more

• YM Biosciences and NRC Biotechnology Research Institute Produce New Breast Cancer Drug Candidates

  YM BioSciences Inc. announced the first results of a collaborative program between YM and the National Research Council of Canada's Biotechnology Research Institute (NRC-BRI). Utilizing YM's IntelliMab(TM) technology, the program is designed to generate novel antibodies that target cell surface rec more

Publications ImmunoGen

• [Research Article] Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors

  Structural knowledge of broadly neutralizing antibodies against HIV-1 guides the design of an immunogen to elicit them. more

• Effect of obesity on the acute inflammatory response in pregnant and cycling female rats

  Abstract Non‐pregnant female rats have a lower inflammatory response to lipopolysaccharide (LPS) than males, and at late stages of gestation, the fever response to this immunogen is almost completely suppressed. We have shown in males that obesity exacerbates sickness responses to pathogenic sti more

• Generation of monoclonal antibodies against the Gal{beta}1-4Gal epitope: A key tool in studies of species-specific glycans expressed in fish, amphibians and birds

  Whereas the Galβ1-4Gal epitope is rarely found in mammalian glycans, it has been found in glycans of various species of non-mammalian vertebrates, such as fish, amphibians and birds. Although glycans containing Galβ1-4Gal in these vertebrates were detected by precise structural analysis of the glyc more

Market studies ImmunoGen

• Leading Anti-Cancer Drugs: World Market Prospects 2011-2021

  What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. We provide research, data and opinions to benefit your work now. What revenues will cancer treatment markets generate from 2011 to 2021 more

Websites ImmunoGen